Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Voorde, Lien Van De; Janssen, Luuk M.; Larue, Ruben T. H. M.; Houben, Ruud; Buijsen, Jeroen; Sosef, Meindert N.; Vanneste, Ben; Schraepen, Marie Céline; Berbée, Maaike

doi:10.1016/j.ejso.2015.05.012

Cited by 20 publications

(18 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Regarding OS, several retrospective cohort studies and meta-analysis studies suggested that metformin use was found to be associated with higher OS in various human solid cancers including endometrial, breast, ovarian, lung, and esophagus. 13,14,16,21,23 In our study, we found that patients with metformin use had a higher OS than those without metformin use. However, no significant differences were found between the 2 groups.…”

Section: Discussionsupporting

confidence: 48%

“…However, we found that patients with metformin use were more likely to be overweight (borderline significant, P = 0.057) which is in line with earlier studies. 13,20,21 This may be explained by the fact that metformin is typically used in the treatment of patients with type 2 DM who are obese. 8 We also found that patients with cervical cancer with type 2 DM who used metformin had a lower recurrence rate (P = 0.011).…”

Section: Discussionmentioning

confidence: 99%

“…However, the DFS benefit associated with metformin use in cancer patients with DM has also been shown in various human solid cancers including ovarian, endometrial, lung, esophagus, and prostate. 12,13,15,17,21,22 Romero et al 12 reported that the association of metformin use and increased progression-free survival, but not OS, remained significant after controlling for standard clinicopathologic parameters in stage I-IV epithelial ovarian, fallopian, or peritoneal cancer. Similarly, a meta-analysis of 21 epidemiological observational studies by Yu et al 22 demonstrated that metformin use seems to be associated with a significant reduction in the cancer risk and biochemical recurrence of prostate cancer, but not in all-cause mortality of patients with prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus

Hanprasertpong

Jiamset²,

Geater³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus

Hanprasertpong

Jiamset²,

Geater³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…It is also possible that metformin has tumour suppressive effects that may be based on its metabolic effects. [29][30][31][32] In the Women's Health Initiative Figure 3. (a) Association between baseline statin usage and all-cause and cause-specific mortality by cancer type.…”

Section: Discussionmentioning

confidence: 99%

Risk of Cause‐Specific Death in Individuals with Cancer—Modifying Role Diabetes, Statins and Metformin

Haukka

Niskanen

Auvinen

2017

Intl Journal of Cancer

View full text Add to dashboard Cite

Both diabetes mellitus (DM) and cancer are common diseases and they frequently occur in the same patients. We investigated the all-cause and cause-specific mortality dynamics in relation to baseline DM, statin use and metformin use. The study population consisted of 39,900 incident cancer cases from Finland, 19,822 patients were free of DM at the start of follow-up and 20,078 had DM. Mortality from all causes, and cancer, cardiovascular (CVD) and other causes was analysed using Poisson regression model with the following variables: sex, age, DM, statin and metformin usage in baseline, cancer type and stage and calendar period. Statin usage was associated with a reduced cancer-specific mortality with incidence rate ratio (IRR) 0.72 (95% confidence interval 0.69-0.74), IRR for CVD mortality was 0.95 (0.88-1.02) and for other causes 0.64 (0.56-0.74). In a sub-population of DM patients, IRR for metformin in all-cause mortality was 0.74 (0.71-0.78), in cancer mortality 0.75 (0.72-0.79), in CVD mortality 0.75 (0.68-0.83) and other causes 0.68 (0.60-0.78). In conclusion, our register-based study of survival after cancer diagnosis showed that patients with diabetes had substantially poorer outcome in all measures. An association between baseline statin usage and lower all-cause, cancer and cardiovascular mortality was modified by cancer type. The effect of statin use was largest for breast and colorectal cancer. Metformin usage in a subpopulation of oral antidiabetic users was in general associated with lower mortality, but this association was modified by cancer type. The association was strongest for liver, colorectal and breast cancer.

show abstract

“…In addition, Bowler et al also found lower mortality rate for patients with metformin verse those with sulfonylurea [11]. A recent retrospective study with 196 patients reported that the overall survival rate of EC patient with long-term treatment of metformin was all higher, while the metastasis rate was lower than those without treatment of metformin [12–13]. Furthermore, a number of studies have confirmed that metformin inhibited the proliferation ability of EC, lung cancer, gastric cancer and others in vitro and in vivo [14, 15].…”

Section: Introductionmentioning

confidence: 99%

Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin

et al. 2017

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis in China. Chemotherapy now is one of the most frequently used treatments for patients with ESCC in middle or late stage, however the effects were often limited by increased chemoresistance or treatment toxicity. So it is urgent to find new drugs to treat ESCC patients. Metformin with low cost and toxicity has proved to have anti-cancer effects in numerous cancers, while its role and mechanism in ESCC has seldom been studied. In the present study, we found that metformin exhibited not only an anti-proliferation ability in a dose and time dependent manner but also a proapoptosis effect in a dose dependent manner in ESCC cell line KYSE450. Our in vivo experiment also showed that metformin markedly inhibited KYSE450 xenograft tumors growth compared to those treated with normal saline. What’s more, no obvious toxic reactions were observed. To further explore the underlying mechanism, we found that metformin treatment could significantly damp the expression of 4EBP1 and S6K1 in KYSE 450 cells in vitro and in vivo, furthermore, the p-4EBP1 and p-S6K1 expression in KYSE 450 cells were also inhibited greatly in vitro and in vivo. During the therapy of cancer, in order to overcome side effects, combination therapy was often used. In this paper, we demonstrated that metformin potentiated the effects of cisplatin via inhibiting cell proliferation and promoting cell apoptosis. Taken together, metformin owned the potential anti-cancer effect on ESCC in monotherapy or was combined with cisplatin and these results laid solid basis for the use of metformin in ESCC.

show abstract

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Abstract: In our population-based study, the use of metformin was associated with an improved overall and distant metastasis-free survival rate in patients with oesophageal cancer. These data are complementary to one other clinical study and warrant further prospective study.

Cited by 20 publications

References 45 publications

The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus

The Effect of Metformin on Oncological Outcomes in Patients With Cervical Cancer With Type 2 Diabetes Mellitus

Risk of Cause‐Specific Death in Individuals with Cancer—Modifying Role Diabetes, Statins and Metformin

Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin

Contact Info

Product

Resources

About